Technical Analysis for ADMS - Adamas Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade D 9.69 1.47% 0.14
ADMS closed up 1.47 percent on Wednesday, December 12, 2018, on 54 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Down Down
See historical ADMS trend table...

Date Alert Name Type % Chg
Dec 12 Boomer Sell Setup Bearish Swing Setup 0.00%
Dec 12 Narrow Range Bar Range Contraction 0.00%
Dec 12 NR7 Range Contraction 0.00%
Dec 12 Inside Day Range Contraction 0.00%
Dec 11 New 52 Week Closing Low Bearish 1.47%
Dec 11 Inside Day Range Contraction 1.47%
Dec 11 Down 3 Days in a Row Weakness 1.47%
Dec 11 Down 4 Days in a Row Weakness 1.47%
Dec 11 Down 5 Days in a Row Weakness 1.47%
Dec 10 New 52 Week Closing Low Bearish -1.22%

Older signals for ADMS ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Adamas Pharmaceuticals, Inc. focuses on the development and commercialization of therapeutics for chronic disorders of the central nervous systems (CNS) in the United States. The company is developing its lead product candidate, ADS-5102 that has completed a Phase 2/3 clinical study for levodopa induced dyskinesia, a complication of Parkinson's disease; and as a treatment for chronic behavioral symptoms associated with traumatic brain injury. It is also developing ADS-8800 and ADS-9000 series of products for use in a range of CNS indications; ADS-8704, a fixed-dose combination of memantine and donepezil for the treatment of moderate to severe dementia related to alzheimer's disease; and ADS-8902, a triple combination antiviral drug therapy for influenza. In addition, the company develops memantine-based therapeutics portfolio includes Namenda XR and MDX-8704, which are used in the treatment of dementia associated with moderate to severe alzheimer's disease. Adamas Pharmaceuticals, Inc. was founded in 2000 and is headquartered in Emeryville, California.
Is ADMS a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 44.0
52 Week Low 9.03
Average Volume 665,379
200-Day Moving Average 22.6612
50-Day Moving Average 13.994
20-Day Moving Average 10.329
10-Day Moving Average 10.073
Average True Range 0.8506
ADX 39.77
+DI 14.7183
-DI 34.0658
Chandelier Exit (Long, 3 ATRs ) 10.6982
Chandelier Exit (Short, 3 ATRs ) 11.581799999999999
Upper Bollinger Band 11.3497
Lower Bollinger Band 9.3083
Percent B (%b) 0.19
BandWidth 19.763772
MACD Line -1.1652
MACD Signal Line -1.3582
MACD Histogram 0.193
Fundamentals Value
Market Cap 218.16 Million
Num Shares 22.5 Million
EPS -2.99
Price-to-Earnings (P/E) Ratio -3.24
Price-to-Sales 2373.51
Price-to-Book 4.03
PEG Ratio -0.06
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 10.01
Resistance 3 (R3) 10.03 9.95 9.95
Resistance 2 (R2) 9.95 9.87 9.94 9.93
Resistance 1 (R1) 9.82 9.82 9.89 9.80 9.92
Pivot Point 9.74 9.74 9.77 9.73 9.74
Support 1 (S1) 9.61 9.66 9.68 9.59 9.46
Support 2 (S2) 9.53 9.61 9.52 9.45
Support 3 (S3) 9.40 9.53 9.43
Support 4 (S4) 9.38